Cargando…

Serum RANKL levels in Chinese patients with ankylosing spondylitis: a meta-analysis

OBJECTIVE: We aimed to determine the association between serum receptor activator of nuclear factor-kappa B ligand (sRANKL) levels and ankylosing spondylitis (AS) in Chinese patients. METHODS: The PubMed, Cochrane Library, Embase, Chinese Biomedical Database, Web of Science, China National Knowledge...

Descripción completa

Detalles Bibliográficos
Autores principales: Ni, Feifei, Zhang, Yanchao, Peng, Yi, Peng, Xiaoxiao, Li, Jianjun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8522048/
https://www.ncbi.nlm.nih.gov/pubmed/34663371
http://dx.doi.org/10.1186/s13018-021-02721-x
_version_ 1784585016924176384
author Ni, Feifei
Zhang, Yanchao
Peng, Yi
Peng, Xiaoxiao
Li, Jianjun
author_facet Ni, Feifei
Zhang, Yanchao
Peng, Yi
Peng, Xiaoxiao
Li, Jianjun
author_sort Ni, Feifei
collection PubMed
description OBJECTIVE: We aimed to determine the association between serum receptor activator of nuclear factor-kappa B ligand (sRANKL) levels and ankylosing spondylitis (AS) in Chinese patients. METHODS: The PubMed, Cochrane Library, Embase, Chinese Biomedical Database, Web of Science, China National Knowledge Infrastructure, VIP, and Wan Fang databases were searched for studies conducted before October 1, 2020, without language restrictions. STATA version 12.0 and Revman version 5.3 were used to analyze the data. The standard mean differences (SMDs) and corresponding 95% confidence intervals (95% CIs) were calculated. RESULTS: Twelve clinical case–control studies, including 585 patients with AS and 423 healthy controls, were included. The combined SMD for sRANKL suggested that the sRANKL level was significantly higher in Chinese patients with AS than in healthy controls (SMD: 3.27, 95% CI 2.11–4.43, P < 0.00001). Serum RANKL-related factor osteoprotegerin (OPG) levels (SMD: 0.86, 95% CI 0.09–1.64, P < 0.03) were lower in the Chinese patients with AS than in healthy controls, and the RANKL/OPG ratio (SMD = 1.05, 95% CI 0.64–1.46, P < 0.00001) in Chinese patients with AS was approximately the same as that of healthy controls. Subgroup analysis indicated that patients from North and South China had higher sRANKL levels than controls; the sRANKL levels of patients from South China were higher in the subgroup with a Bath Ankylosing Spondylitis Functional Index (BASFI) of > 4 than those of patients in other subgroups. In terms of duration, patients with AS for > 8 years had higher sRANKL levels than health controls. Other subgroup analyses were conducted by region, language, source of control, age, and Bath Ankylosing Spondylitis Disease Activity Index (BASDAI). In these subgroups, the sRANKL levels were significantly higher in the patients with AS than in healthy controls. The BASFI and BASDAI were sources of heterogeneity. CONCLUSIONS: The sRANKL levels are higher in Chinese patients with AS, especially among those from South China. sRANKL levels may be positively correlated with the pathogenesis of AS among Chinese patients.
format Online
Article
Text
id pubmed-8522048
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-85220482021-10-21 Serum RANKL levels in Chinese patients with ankylosing spondylitis: a meta-analysis Ni, Feifei Zhang, Yanchao Peng, Yi Peng, Xiaoxiao Li, Jianjun J Orthop Surg Res Research Article OBJECTIVE: We aimed to determine the association between serum receptor activator of nuclear factor-kappa B ligand (sRANKL) levels and ankylosing spondylitis (AS) in Chinese patients. METHODS: The PubMed, Cochrane Library, Embase, Chinese Biomedical Database, Web of Science, China National Knowledge Infrastructure, VIP, and Wan Fang databases were searched for studies conducted before October 1, 2020, without language restrictions. STATA version 12.0 and Revman version 5.3 were used to analyze the data. The standard mean differences (SMDs) and corresponding 95% confidence intervals (95% CIs) were calculated. RESULTS: Twelve clinical case–control studies, including 585 patients with AS and 423 healthy controls, were included. The combined SMD for sRANKL suggested that the sRANKL level was significantly higher in Chinese patients with AS than in healthy controls (SMD: 3.27, 95% CI 2.11–4.43, P < 0.00001). Serum RANKL-related factor osteoprotegerin (OPG) levels (SMD: 0.86, 95% CI 0.09–1.64, P < 0.03) were lower in the Chinese patients with AS than in healthy controls, and the RANKL/OPG ratio (SMD = 1.05, 95% CI 0.64–1.46, P < 0.00001) in Chinese patients with AS was approximately the same as that of healthy controls. Subgroup analysis indicated that patients from North and South China had higher sRANKL levels than controls; the sRANKL levels of patients from South China were higher in the subgroup with a Bath Ankylosing Spondylitis Functional Index (BASFI) of > 4 than those of patients in other subgroups. In terms of duration, patients with AS for > 8 years had higher sRANKL levels than health controls. Other subgroup analyses were conducted by region, language, source of control, age, and Bath Ankylosing Spondylitis Disease Activity Index (BASDAI). In these subgroups, the sRANKL levels were significantly higher in the patients with AS than in healthy controls. The BASFI and BASDAI were sources of heterogeneity. CONCLUSIONS: The sRANKL levels are higher in Chinese patients with AS, especially among those from South China. sRANKL levels may be positively correlated with the pathogenesis of AS among Chinese patients. BioMed Central 2021-10-18 /pmc/articles/PMC8522048/ /pubmed/34663371 http://dx.doi.org/10.1186/s13018-021-02721-x Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Ni, Feifei
Zhang, Yanchao
Peng, Yi
Peng, Xiaoxiao
Li, Jianjun
Serum RANKL levels in Chinese patients with ankylosing spondylitis: a meta-analysis
title Serum RANKL levels in Chinese patients with ankylosing spondylitis: a meta-analysis
title_full Serum RANKL levels in Chinese patients with ankylosing spondylitis: a meta-analysis
title_fullStr Serum RANKL levels in Chinese patients with ankylosing spondylitis: a meta-analysis
title_full_unstemmed Serum RANKL levels in Chinese patients with ankylosing spondylitis: a meta-analysis
title_short Serum RANKL levels in Chinese patients with ankylosing spondylitis: a meta-analysis
title_sort serum rankl levels in chinese patients with ankylosing spondylitis: a meta-analysis
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8522048/
https://www.ncbi.nlm.nih.gov/pubmed/34663371
http://dx.doi.org/10.1186/s13018-021-02721-x
work_keys_str_mv AT nifeifei serumrankllevelsinchinesepatientswithankylosingspondylitisametaanalysis
AT zhangyanchao serumrankllevelsinchinesepatientswithankylosingspondylitisametaanalysis
AT pengyi serumrankllevelsinchinesepatientswithankylosingspondylitisametaanalysis
AT pengxiaoxiao serumrankllevelsinchinesepatientswithankylosingspondylitisametaanalysis
AT lijianjun serumrankllevelsinchinesepatientswithankylosingspondylitisametaanalysis